VAI TRÒ CỦA THUỐC CHẸN BÊTA GIAO CẢM THẾ HỆ MỚI TRONG ĐIỀU TRỊ CÁC BỆNH LÝ TIM MẠCH: CHUYÊN ĐỀ VỀ NEBIVOLOL

Nguyễn Lân Việt; Phạm Gia Khải; Đặng Vạn Phước

Các tác giả

Nguyễn Lân Việt Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai
Phạm Gia Khải Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai
Đặng Vạn Phước Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai

Tóm tắt

VAI TRÒ CỦA THUỐC CHẸN BÊTA GIAO CẢM THẾ HỆ MỚI TRONG ĐIỀU TRỊ CÁC BỆNH LÝ TIM MẠCH:

Tài liệu tham khảo

1. Ignarro LJ. Cardiovasc Ther 2008; 26: 115-134.

2. Ignarro LJ. Proc Natl Acad Sci USA 2002; 99: 7816-7817.

3. BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD: Health out-comes associated with antihypertensive therapies used as first-line agents: a systematic review and meta- analysis. JAMA1997;277:739 –745.

4. Gottlieb SS, McCarter RJ: Comparative effects of three ß block-ers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarction. Am J Cardiol 2001;87:823– 826.

5. Foody JM, Farrell MH, Krumholz HM: Beta Blocker therapy in heartfailure: scientific review. JAMA 2002;287:883– 889.

6. CIBIS II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomised trial.

Lancet 1999;353:9 –13.

7. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–2007.

8. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK,DeMets DL, and the Carvedilol Prospective Randomized Cumula-tive Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.

9. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular com-plications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713–720.

10. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Wright JT, Oakes R, Lukas MM, Anderson KM, Bell DSH, and the GEMINI Investigators: Metabolic effects of carvedilol vs meto-prolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial. JAMA 2004;292:2227–2236. 175SAJH–December 2005– VOL. 18, NO. 12, Part 2 -BLOCKERS IN CV DISEASE

11. Mangrella M, Rossi F, Fici F, Rossi F: Pharmacology of nebivolol. Pharmacol Res 1998;38:419 – 431.

12. Kuroedov A, Cosentino F, Lüscher TF: Pharmacological mechanisms of clinically favorable properties of a selective 1-adrenoreceptor an-tagonist, nebivolol. Cardiovasc Drug Rev 2004;22:155–168.

13. Van Peer A, Snoeck E, Woestenborghs R, Van de Velde V, Mannens G, Meuldermans W, Heykants J: Clinical pharmacokinetics of nebivolol: a review. Drug Invest 1991;3(Suppl 1):25–30.

14. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, Reneman RS, Janssen PAJ: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective 1 -adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11:552–563.

15. Kamp O, Sieswarda GT, Visser CA: Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003;92:344 –348.

16. Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JI: A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997;11:139 –144.

17. Fallois JV, Faulhaber H-D: Nebivolol, a ß-blocker of the third generation: the current treatment of arterial hypertension: results of a multicenter observational study. Praxis 2001;90:435– 441.

18. Van Nueten L, Taylor FR, Robertson JIS: Nebivolol vs atenolol and placebo in essential hypertension: a double- blind randomised trial. J Hum Hypertens 1998;12:135–140.

19. Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G: Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl 2003;2:35– 40.

20. Uhlír˘ O, Fejfus˘ a M, Havránek K, Lefflerová K, Vojác˘ ek J, Widim-sky´ J, Winterová J, Zeman K: Nebivolol versus metoprolol in the treatment of hypertension. Drug Invest 1991;3(Suppl 1):107–110.

21. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson J I : Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind, randomised trial. J Hum Hypertens 1997;11:813– 819.

22. Lacourciére Y, Lefebvre J, Poirier L, Archamault F, Arnott W: A double-blind crossover comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension. Am J Ther 1994;1:74 – 80.

23. Rosei EA, Rizzoni D, Comini S, Boari G, and the Nebivolol-Lisinopril Study Group: Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press 2003;12(Suppl 1):30 –35.

24. Van Nueten L, Lacourciére Y, Vyssoulis G, Korlipara K, Marcadet DM, Dupont AG, Robertson JIS: Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther 1998;5:237–243.

25. Mazza A, Gil-Extremera B, Maldonato A, Toutouzas T, Pessina AC: Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press 2002;11:182–188.

26. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Park-homenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker S, Thompson SG, Poole-Wilson PA, and the SENIORS Investigators: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly pa-tients with heart failure (SENIORS). Eur Heart J 2005;26:215–225.

27. George L Bakris, Jan N Basile, Thomas D Giles, Addison A Taylor: The role of Nitric Oxide in Improving Endothelial Function and Cardivascular Health: Focus on Nebivolol. The Am J Med 2010; 123:S2-S8.

28. Luc M Van Bortel, Francesco Fici, Flavio Mascagni: Efficacy and Tolerability of Nebivolol Compared with Other Antihypertensive Drugs. Am J Cardiovasc Drugs 2008; 8 (1): 35-44.

29. Priit Kampus, Martin Serg, Jaak Kals, Maksim Zagura, Piibe Muda, Kulliki Karu, Mihkel Zilmer, Jaan Eha: Differential Effects of Nebivolol and Metoprolol on Central Aortic Pressure and Left Ventricular Wall Thickness. Hypertension 2011; 57:1122-1128.